Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman; Marian A. Rollins-Raval; Jay S. Raval; Yara A. Park; Marshall Mazepa; Alice Ma

doi:10.1097/MJT.0000000000000517

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original language	English (US)
Pages (from-to)	E270-E272
Journal	American journal of therapeutics
Volume	25
Issue number	2
DOIs	https://doi.org/10.1097/MJT.0000000000000517
State	Published - Mar 1 2018

Bibliographical note

Funding Information:
1Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC; and 2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC. Supported by National Institutes of Health, National Heart, Lung, and Blood Institute, Grant T32HL007149 (J.D.B.). The authors have no conflicts of interest to declare. *Address for correspondence: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599-7305. E-mail: alice_ma@med.unc.edu

Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

Bortezomib
Immune-mediated thrombocytopenia purpura

Access

10.1097/MJT.0000000000000517

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753577

OpenUrl availability

Full text

Cite this

@article{7898ecb17c774c79b942cea3ad56a798,

title = "Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura",

abstract = "The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.",

keywords = "Bortezomib, Immune-mediated thrombocytopenia purpura",

author = "Beckman, {Joan D.} and Rollins-Raval, {Marian A.} and Raval, {Jay S.} and Park, {Yara A.} and Marshall Mazepa and Alice Ma",

note = "Funding Information: 1Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC; and 2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC. Supported by National Institutes of Health, National Heart, Lung, and Blood Institute, Grant T32HL007149 (J.D.B.). The authors have no conflicts of interest to declare. *Address for correspondence: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599-7305. E-mail: alice_ma@med.unc.edu Publisher Copyright: {\textcopyright} 2017 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2018",

month = mar,

day = "1",

doi = "10.1097/MJT.0000000000000517",

language = "English (US)",

volume = "25",

pages = "E270--E272",

journal = "American journal of therapeutics",

issn = "1075-2765",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

AU - Beckman, Joan D.

AU - Rollins-Raval, Marian A.

AU - Raval, Jay S.

AU - Park, Yara A.

AU - Mazepa, Marshall

AU - Ma, Alice

N1 - Funding Information: 1Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC; and 2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC. Supported by National Institutes of Health, National Heart, Lung, and Blood Institute, Grant T32HL007149 (J.D.B.). The authors have no conflicts of interest to declare. *Address for correspondence: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599-7305. E-mail: alice_ma@med.unc.edu Publisher Copyright: © 2017 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

AB - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

KW - Bortezomib

KW - Immune-mediated thrombocytopenia purpura

UR - http://www.scopus.com/inward/record.url?scp=85053903627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053903627&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000517

DO - 10.1097/MJT.0000000000000517

M3 - Article

C2 - 29293474

AN - SCOPUS:85053903627

SN - 1075-2765

VL - 25

SP - E270-E272

JO - American journal of therapeutics

JF - American journal of therapeutics

IS - 2

ER -

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this